AlphaValue/Baader Europe: Novo Nordisk's New Obesity Drug Holds Promise Despite Disappointing Late-Stage Data

MT NewswiresDec 23 19:29

Tech Stocks Eye Christmas Gains, Microstrategy Tumbles As Bitcoin Dips To $93,000: What's Driving Markets Monday?

Benzinga02:19

European Equities Traded in the US as American Depositary Receipts Start Week Down Slightly in Monday Trading

MT Newswires00:04

NVO Stock Plunges as Obesity Drug CagriSema Misses Target in Phase III

Zacks Dec 23 22:35

BMO Capital has lowered the Target Price for Novo-Nordisk A/S to $105.

Gelonghui December 23 | BMO Capital: Downgraded the Target Price of Novo-Nordisk A/S from $156 to $105, maintaining an 'outperform market' rating. (Gelonghui)

Gelonghui FinanceDec 23 22:24 · Ratings

Major Bank Rating | TD Cowen: Downgraded Novo-Nordisk A/S Target Price to $105, maintaining "Buy" rating.

On December 23, Glory Holdings reported that TD Cowen has lowered the Target Price for Novo-Nordisk A/S from $155 to $105, maintaining a Buy rating. TD Cowen pointed out that despite the trial results of CagriSema being below expectations, Novo-Nordisk A/S has a strong market position due to its main drugs, the potential of the new CagriSema trials, and a vibrant product line. (Glory Holdings)

Gelonghui FinanceDec 23 21:21 · Ratings